세계의 DNA 진단 시장 : 시장 규모, 점유율, 동향 : 제공 제품별, 기술별, 검체별, 용도별, 최종 사용자별, 지역별 예측(-2029년)
DNA Diagnostics Market Size, Share & Trends by Product, Technology, Application (Infectious Disease, Oncology), Specimen - Global Forecast to 2029
상품코드:1511375
리서치사:MarketsandMarkets
발행일:2024년 07월
페이지 정보:영문 334 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계 DNA 진단 시장 규모는 2024년에 133억 달러로 예측되고, 2029년에는 212억 달러에 이를 것으로 예상되며, 예측 기간 중 복합 연간 성장률(CAGR)은 9.7%가 될 전망입니다.
DNA 진단 시장의 성장은 주로 만성 질환과 감염의 확산을 증가시키고, 개인화된 의료를 위한 DNA 진단의 진보, 건강 관리 관련 기업에 의한 자금 조달 증가로 이어집니다. 개인화된 의약품은 충분한 정보를 바탕으로 임상 판단을 내리고 부작용의 위험을 줄이는 데 도움이 됩니다. 이와 같이 맞춤형 의료에 대한 수요 증가는 DNA 진단 시장에서 사업을 전개하는 기업에게 향후 수년간 큰 성장 기회를 가져올 것으로 기대되고 있습니다.
조사 범위
조사 대상년도
2022년-2029년
기준년
2023년
예측 기간
2024년-2029년
검토 단위
금액(10억 달러)
부문별
제공 제품별, 기술별, 시료별, 용도별, 최종 사용자별, 지역별
대상 지역
북미, 유럽, 아시아태평양, 중동, 아프리카, 라틴아메리카, GCC 국가
DNA 진단 시장은 시약, 키트, 장비, 서비스 및 소프트웨어로 구분됩니다. 시약 및 키트는 자주 필요하기 때문에 경상적인 비용이 되고, 이 경상적인 구매 요건이 시장 성장의 주요 요인 중 하나가 되고 있습니다. 다양한 검사 요구에 대응할 수 있는 시약 및 키트의 다용도는 광범위한 사용과 예측 기간 동안 시장 수요에 기여합니다.
기술별로 DNA 진단 시장은 중합효소 연쇄반응(PCR), 마이크로어레이, in situ 하이브리드화, 시퀀싱 기술, 질량분석, 기타 기술로 구분됩니다. PCR 기술은 광범위한 표준화를 거쳐 다양한 실험실과 플랫폼간에 일관되고 신뢰할 수 있는 결과를 보장합니다. 현재 PCR은 사용 편의성, 비용 효율성, 빠른 측정 시간(4 - 6시간)으로 진단에 가장 널리 사용되는 기술 중 하나입니다. 또한 소형 PCR 장치는 유지 보수가 거의 필요하지 않을 수 있습니다. 이러한 요인은이 부문의 성장에 기여합니다.
표본별로 DNA 진단 시장은 혈액, 혈청, 혈장, 소변 및 기타 표본으로 구분됩니다. 혈액 채취 및 처리 절차는 광범위하게 표준화되어 일관된 시료 품질과 검사 결과의 신뢰성을 보장합니다. 표준화된 프로토콜과 품질 관리 조치는 혈액 시료에서 수행되는 DNA 진단 검사의 정확성과 재현성을 높입니다. 2023년 DNA 진단 시장에서 이 분야가 가장 큰 시장 점유율을 차지하는 것은 어느 것일까?
DNA 진단 시장은 용도별로 감염증 진단, 종양 검사, 출생 전 진단, 착상 전 진단, 근원성 질환, 기타 용도로 구분됩니다. 종양 검사에 대한 수요의 급증은 암의 진단과 치료의 전망을 바꾸고 있는 다양한 요인에 뒷받침되고 있습니다. DNA 진단 검사는 의사가 유전 물질의 질병에 대한 소인을 조사하고 암과 같은 질병을 조기에 진단 할 수있게합니다. 이 분야의 성장은 기술의 진보와 암의 이환율 증가에 의해서도 견인되고 있습니다.
최종 사용자별로 보면 DNA 진단 시장은 병원 및 진료소, 진단 실험실, 기타 최종 사용자로 구분됩니다. 병원에서는 검사실 관리에 드는 비용과 기술적 문제를 줄이기 위해 진단 검사를 진단 실험실에 위탁하는 경우가 늘고 있습니다. 많은 중소 병원 및 진료소가이 동향을 채택하고 있으며,이 부문의 성장을 견인하고 있습니다.
본 보고서에서는 세계 DNA 진단 시장에 대해 조사했으며, 제공 제품별, 기술별, 검체별, 용도별, 최종 사용자별, 지역별 동향 및 시장 진출기업 프로파일 등을 정리했습니다.
목차
제1장 서론
제2장 조사 방법
제3장 주요 요약
제4장 중요 인사이트
제5장 시장 개요
소개
시장 역학
가격 분석
밸류체인 분석
공급망 분석
생태계 분석
Porter's Five Forces 분석
규제 분석
기술 분석
무역 분석
특허 분석
2024년-2025년의 주된 회의와 이벤트
PESTLE 분석
고객의 비즈니스에 영향을 미치는 동향/혼란
주요 이해관계자와 구매 기준
투자와 자금조달 시나리오
제6장 DNA 진단 시장 : 제공 제품별
소개
시약 및 키트
기기
서비스,소프트웨어
제7장 DNA 진단 시장 : 기술별
소개
중합효소 연쇄반응
마이크로어레이
in situ 하이브리드화
시퀀싱
질량 분석
기타
제8장 DNA 진단 시장 : 검체별
소개
혈액, 혈청, 혈장
소변
기타
제9장 DNA 진단 시장 : 용도별
소개
감염증 진단
종양학 검사
근원성 질환
출생 전
착상 전
기타
제10장 DNA 진단 시장 : 최종 사용자별
소개
진단 실험실
병원 및 클리닉
기타
제11장 DNA 진단 시장 : 지역별
소개
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
GCC 국가
제12장 경쟁 구도
개요
주요 진입기업의 전략/비책
수익 분석
시장 점유율 분석
기업평가 매트릭스 : 주요 진입기업(2023년)
기업평가 매트릭스 : 스타트업/중소기업(2023년)
평가 및 재무 지표
브랜드/제품 비교
경쟁 시나리오
제13장 기업 프로파일
주요 진출기업
DANAHER
ILLUMINA, INC.
F. HOFFMANN - LA ROCHE LTD.
BIOMERIEUX
HOLOGIC, INC.
ABBOTT LABORATORIES
THERMO FISHER SCIENTIFIC INC.
QIAGEN
REVVITY, INC.
MYRIAD GENETICS, INC.
SIEMENS HEALTHINEERS AG
기타 기업
BECTON, DICKINSON AND COMPANY
GRIFOLS, SA
QUIDELORTHO CORPORATION
AGILENT TECHNOLOGIES, INC.
DIASORIN SPA
EXACT SCIENCES CORPORATION
GENETIC SIGNATURES
BIOCARTIS
TBG DIAGNOSTICS LIMITED
VELA DIAGNOSTICS
AMOY DIAGNOSTICS CO., LTD.
MOLBIO DIAGNOSTICS PVT. LTD.
제14장 부록
BJH
영문 목차
영문목차
The global DNA diagnostics market is valued at an estimated USD 13.3 billion in 2024 and is projected to reach USD 21.2 billion by 2029, at a CAGR of 9.7% during the forecast period. Growth in the DNA diagnostics market is primarily driven by the increasing prevalence of chronic and infectious diseases, advancements in DNA diagnostics for personalized medicine, and increasing funding by healthcare-based companies. Personalized medicines help in making informed clinical decisions and alleviating the risk of adverse events. Thus, the increasing demand for personalized medicines is expected to offer significant growth opportunities for players operating in the DNA diagnostics market in the coming years.
Scope of the Report
Years Considered for the Study
2022-2029
Base Year
2023
Forecast Period
2024-2029
Units Considered
Value (USD Billion)
Segments
By Offering, Technology, Specimen, Application, End User, and region
Regions covered
North America, Europe, Asia Pacific, Middle East & Africa, Latin America, and the GCC Countries
"The reagents & kits segment is projected to witness highest growth rate in the DNA diagnostics market, by offering, during the forecast period"
Based on offering, the DNA diagnostics market is segmented into reagents & kits, instruments, and services & software. The frequent need for reagents & kits makes them a recurrent cost, and this recurrent purchasing requirement is one of the key contributors to market growth. The versatility of reagents & kits in accommodating diverse testing needs contributes to their extensive usage and market demand during the forecast period.
"The polymerase chain reaction (PCR) segment is projected to witness the highest growth rate in the DNA diagnostics market, by technology, during the forecast period."
Based on technology, the DNA diagnostics market is segmented into polymerase chain reaction (PCR), microarrays, in situ hybridization, sequencing technology, mass spectroscopy, and other technologies. PCR techniques have undergone extensive standardization, ensuring consistent and reliable results across different laboratories and platforms. Currently, PCR is one of the most widely used technologies in diagnostics due to its ease of use, cost-effectiveness, and quick turnaround time (4 to 6 hours). Small PCR instruments may need little or no maintenance. These factors are contributing to growth of this segment.
"The blood, serum, and plasma segment accounted for the largest market share of DNA diagnostics market, in 2023, by specimen"
Based on specimen, the DNA diagnostics market is segmented into blood, serum, and plasma, urine, and other specimens. Blood collection and processing procedures have undergone extensive standardization, ensuring consistent sample quality and reliability of test results. Standardized protocols and quality control measures enhance the accuracy and reproducibility of DNA diagnostic tests performed on blood samples. Which accounts for the largest market share of this segment in the DNA diagnostics market in 2023.
"The oncology testing segment is projected to witness the highest growth rate in the DNA diagnostics market, by application, during the forecast period".
Based on application, the DNA diagnostics market is segmented into infectious disease diagnostics, oncology testing, prenatal, pre-implantation, myogenic disorders, and other applications. The surge in demand for oncology testing is fueled by various factors that are transforming the landscape of cancer diagnostics and treatment. DNA diagnostic tests enable physicians to study the predisposition of genetic materials to diseases and diagnose diseases, such as cancer, at an early stage. The growth of this segment is also driven by technological advancements and the increasing incidence of cancer.
"The diagnostic laboratories segment accounted for the largest share of the DNA diagnostics market in 2023, by end user".
Based on end users, the DNA diagnostics market is segmented into hospitals and clinics, diagnostic laboratories, and other end users. Hospitals have increasingly outsourced diagnostic tests to diagnostic laboratories to reduce the costs and technical issues in managing laboratories. Many small and medium-sized private hospitals and clinics have adopted this trend, thereby driving growth in this segment.
"The Asia Pacific region is projected to witness highest growth rate in the DNA diagnostics market during the forecast period"
The global DNA diagnostics market is segmented into six regions - North America, Europe, Asia Pacific, the Middle East & Africa, Latin America, and the GCC Countries. The Asia Pacific is projected to register the highest CAGR in the DNA diagnostics market during the forecast period. Due to factors like government initiatives to raise awareness about early disease detection and routine health checkups, steadily rising healthcare costs, an increase in hospitals and clinical diagnostics laboratories in China and India, and strengthening research bases for diagnostic procedures across China, Japan, and India, the Asia Pacific market is anticipated to grow at the highest rate during the forecast period.
The primary interviews conducted for this report can be categorized as follows:
By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
By Designation: C-level - 27%, D-level - 18%, and Others - 55%
By Region: North America - 35%, Europe - 26%, Asia Pacific - 24%, Latin America - 12%, Middle East & Africa - 2%, and the GCC Countries - 1%
Lists of Companies Profiled in the Report:
Illumina, Inc. (US), Danaher Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMerieux (France), Hologic, Inc. (US), QIAGEN (Germany), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), Revvity, Inc. (US), Siemens Healthineers AG (Germany), Agilent Technologies, Inc. (US), Becton, Dickinson and Company (BD) (US), DiaSorin S.p.A. (Italy), Grifols S.A. (Spain), Quidelortho Corporation (US), Amoy Diagnostics Co., Ltd (China), Molbio Diagnostics Pvt. Ltd. (India), Biocartis (Belgium), Exact Sciences Corporation (US), TBG Diagnostics Ltd (Australia), Genetic Signatures (Australia), and Vela Diagnostics (Singapore).
Research Coverage:
In this report, the DNA diagnostics market has been categorized based on technology (polymerase chain reaction (PCR), microarrays, in situ hybridization, sequencing technology, mass spectroscopy, and other technologies), specimen (blood, serum, and plasma, urine, and other specimens), offering (reagents & kits, instruments, and services & software), end user (diagnostic laboratories, hospitals & clinics, application (infectious disease diagnostic, oncology testing, prenatal, pre-implantation, myogenic disorder, and other applications), and region (North America, Europe, Asia Pacific, Middle East & Africa, Latin America, and the GCC Countries).
The report's coverage includes comprehensive details about the key factors impacting the growth of the DNA diagnostics market, including opportunities, challenges, opportunities, and restraints. To offer insights into their business overview, services offered, significant strategies, acquisitions, and partnerships, product launches, and other recent developments related to the DNA diagnostics market, a thorough analysis of the major industry players has been conducted. This study examines the competitive landscape of emerging DNA diagnostics startups.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall DNA diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, trends, opportunities, and challenges.
The report provides insights on the following pointers:
Analysis of key drivers: (Rising incidence of chronic and infectious diseases, Rising focus on R&D and increased funding by healthcare-based companies, Growing demand for early disease diagnosis an dpersonalized medicine in developing countries, and Technological advancements in DNA diagnostics industry), challenges (Changing regulatory landscape for IVD and DNA diagnostics in US and European Union, Operational barriers and shortage of skills across major markets, and Introductio of alternatives technologies for disease detection and diagnosis), opportunities (Growing significance of companion diagnostics in drug development process, Increasing growth opportunities for DNA diagnostic companies in emerging economies, Advancements in bioinformatics and artificial intelligence in DNA diagnostics and Expansion of direct-to-consumer (DTC) genetic tetsing), and restraints (Unfavourable reimbursement scenario for diagnostic companies, High cost of DNA diagnostic instruments, and Ethical and privacy concerns associated with DNA diagnosis) influencing the growth of the in DNA diagnostics market.
Product Development/Innovation: Detailed insights on research & development activities and new product launches and approvals in the DNA diagnostics market.
Market Development: Comprehensive information about lucrative markets - the report analyses the DNA diagnostics market across varied regions.
Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the DNA diagnostics market
Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Illumina, Inc. (US), Danaher Corporation (US), and F. Hoffmann-La Roche Ltd. (Switzerland) are among others, in the DNA diagnostics market strategies.
TABLE OF CONTENTS
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS OF STUDY
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION
1.3.2 REGIONAL SEGMENTATION
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 DNA DIAGNOSTICS MARKET: RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Primary sources
2.1.2.2 Key data from primary sources
2.1.2.3 Key industry insights
2.1.2.4 Breakdown of primary interviews
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Approach 1: Company revenue estimation approach
FIGURE 4 DNA DIAGNOSTICS MARKET: REVENUE SHARE ANALYSIS
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.2.2 TOP-DOWN APPROACH
FIGURE 6 DNA DIAGNOSTICS MARKET: TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ANALYSIS
2.5 STUDY ASSUMPTIONS
2.6 GROWTH RATE ASSUMPTIONS
2.7 RESEARCH LIMITATIONS
2.7.1 METHODOLOGY-RELATED LIMITATIONS
2.7.2 SCOPE-RELATED LIMITATIONS
2.8 RISK ASSESSMENT
TABLE 1 RISK ASSESSMENT
2.9 RECESSION IMPACT ON DNA DIAGNOSTICS MARKET
3 EXECUTIVE SUMMARY
FIGURE 8 DNA DIAGNOSTICS MARKET, BY OFFERING, 2024 VS. 2029 (USD MILLION)
FIGURE 9 DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
FIGURE 10 DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2024 VS. 2029 (USD MILLION)
FIGURE 11 DNA DIAGNOSTICS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
FIGURE 12 DNA DIAGNOSTICS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
FIGURE 13 GEOGRAPHIC SNAPSHOT OF DNA DIAGNOSTICS MARKET
4 PREMIUM INSIGHTS
4.1 DNA DIAGNOSTICS MARKET OVERVIEW
FIGURE 14 RISING PREVALENCE OF CHRONIC, GENETIC, AND INFECTIOUS DISEASES TO DRIVE MARKET
4.2 ASIA PACIFIC: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY AND COUNTRY (2023)
FIGURE 15 PCR SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2023
4.3 DNA DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 16 CHINA TO REGISTER HIGHEST GROWTH RATE IN DNA DIAGNOSTICS MARKET FROM 2024 TO 2029
4.4 DNA DIAGNOSTICS MARKET: REGIONAL MIX (2024-2029)
FIGURE 17 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
4.5 DNA DIAGNOSTICS MARKET: DEVELOPED VS. DEVELOPING MARKETS
FIGURE 18 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 19 DNA DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising incidence of chronic, infectious, and genetic diseases
FIGURE 20 INCIDENCE OF CANCER, BY REGION, 2022 VS. 2030 VS. 2045 (MILLION)
5.2.1.2 Rising focus on R&D and increased funding by healthcare companies
5.2.1.3 Growing demand for early disease diagnosis and personalized medicine in developing countries
5.2.1.4 Technological advancements in DNA diagnostics industry
5.2.2 RESTRAINTS
5.2.2.1 Unfavorable reimbursement scenario for diagnostic companies
5.2.2.2 High cost of DNA diagnostic instruments
5.2.2.3 Ethical and privacy concerns associated with DNA diagnosis
5.2.3 OPPORTUNITIES
5.2.3.1 Growing significance of companion diagnostics in drug development process
5.2.3.2 Increasing growth opportunities for DNA diagnostic companies in emerging economies
5.2.3.3 Advancements in bioinformatics and artificial intelligence in DNA diagnostics
5.2.3.4 Expansion of direct-to-consumer (DTC) genetic testing
5.2.4 CHALLENGES
5.2.4.1 Changing regulatory landscape for IVD and DNA diagnostics in US and European Union
5.2.4.2 Operational barriers and shortage of skills across major markets
5.2.4.3 Introduction of alternative technologies for disease detection and diagnosis
5.3 PRICING ANALYSIS
5.3.1 PRICING ANALYSIS, BY REGION
TABLE 2 AVERAGE SELLING PRICE OF DNA DIAGNOSTIC PRODUCTS, BY REGION, 2021-2023
5.3.2 PRICING ANALYSIS, BY PRODUCT
TABLE 3 PRICING ANALYSIS OF DNA DIAGNOSTIC PRODUCTS, 2021-2023
5.4 VALUE CHAIN ANALYSIS
FIGURE 21 VALUE CHAIN ANALYSIS OF DNA DIAGNOSTICS MARKET: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASE
5.5 SUPPLY CHAIN ANALYSIS
FIGURE 22 DNA DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
FIGURE 23 DNA DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
5.6.1 DNA DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
5.7 PORTER'S FIVE FORCES ANALYSIS
TABLE 4 DNA DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
FIGURE 24 DNA DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
5.7.1 THREAT OF NEW ENTRANTS
5.7.2 THREAT OF SUBSTITUTES
5.7.3 BARGAINING POWER OF BUYERS
5.7.4 BARGAINING POWER OF SUPPLIERS
5.7.5 INTENSITY OF COMPETITIVE RIVALRY
5.8 REGULATORY ANALYSIS
5.8.1 NORTH AMERICA
5.8.1.1 US
5.8.1.2 Canada
5.8.2 EUROPE
TABLE 5 EUROPE: CLASSIFICATION OF DEVICES
5.8.3 ASIA PACIFIC
5.8.3.1 China
5.8.3.2 Japan
TABLE 6 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.8.3.3 India
5.8.4 LATIN AMERICA
5.8.4.1 Brazil
5.8.4.2 Mexico
5.8.5 MIDDLE EAST
5.8.6 AFRICA
5.8.7 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
*Details on Business overview, Products/Solutions/Services offered, Recent Developments, MnM view, Key strengths, Strategic choices, Weaknesses and competitive threats might not be captured in case of unlisted companies.
13.2 OTHER PLAYERS
13.2.1 BECTON, DICKINSON AND COMPANY
13.2.2 GRIFOLS, S.A.
13.2.3 QUIDELORTHO CORPORATION
13.2.4 AGILENT TECHNOLOGIES, INC.
13.2.5 DIASORIN S.P.A.
13.2.6 EXACT SCIENCES CORPORATION
13.2.7 GENETIC SIGNATURES
13.2.8 BIOCARTIS
13.2.9 TBG DIAGNOSTICS LIMITED
TABLE 347 TBG DIAGNOSTICS LIMITED: COMPANY OVERVIEW
13.2.10 VELA DIAGNOSTICS
TABLE 348 VELA DIAGNOSTICS: COMPANY OVERVIEW
13.2.11 AMOY DIAGNOSTICS CO., LTD.
TABLE 349 AMOY DIAGNOSTICS CO., LTD.: COMPANY OVERVIEW
13.2.12 MOLBIO DIAGNOSTICS PVT. LTD.
TABLE 350 MOLBIO DIAGNOSTICS PVT. LTD.: COMPANY OVERVIEW
